[Preliminary experience with achieving immune tolerance in patients with hemophilia A and circulating factor VIII inhibitor]. 1991

R Scharf, and W Kucharski, and S Lopaciuk, and W Celińska, and A Dmytrow, and K Domański, and S Gonet, and Z Miastkowski, and I Nowakowska, and A Przybylski
Klinika Chirurgiczna, Instytut Hematologii, Warszawa.

The appearance of antibodies to factor VIII is a serious complication in the treatment of haemophilia A. A protocol is presented aiming at suppression of the anticoagulant using continued treatment with factor VIII (25 u/kg b.w. twice weekly). Ten patients with previous maximal factor VIII antibody titre from 7 to 2900 Bethesda units were treated. So far the inhibitor was eradicated in 3 cases treated continuously for from 5 to 20 months. In two of these three cases successful surgical procedures were performed without anamnestic response.

UI MeSH Term Description Entries
D007108 Immune Tolerance The specific failure of a normally responsive individual to make an immune response to a known antigen. It results from previous contact with the antigen by an immunologically immature individual (fetus or neonate) or by an adult exposed to extreme high-dose or low-dose antigen, or by exposure to radiation, antimetabolites, antilymphocytic serum, etc. Immunosuppression (Physiology),Immunosuppressions (Physiology),Tolerance, Immune
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D001803 Blood Transfusion The introduction of whole blood or blood component directly into the blood stream. (Dorland, 27th ed) Blood Transfusions,Transfusion, Blood,Transfusions, Blood
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D005169 Factor VIII Factor VIII of blood coagulation. Antihemophilic factor that is part of the factor VIII/von Willebrand factor complex. Factor VIII is produced in the liver and acts in the intrinsic pathway of blood coagulation. It serves as a cofactor in factor X activation and this action is markedly enhanced by small amounts of thrombin. Coagulation Factor VIII,Factor VIII Clotting Antigen,Factor VIII Coagulant Antigen,Factor VIII Procoagulant Activity,Thromboplastinogen,Blood Coagulation Factor VIII,F VIII-C,Factor 8,Factor 8 C,Factor Eight,Factor VIIIC,Hyate-C,Hyatt-C,F VIII C,Hyate C,HyateC,Hyatt C,HyattC
D005340 Fibrinogen Plasma glycoprotein clotted by thrombin, composed of a dimer of three non-identical pairs of polypeptide chains (alpha, beta, gamma) held together by disulfide bonds. Fibrinogen clotting is a sol-gel change involving complex molecular arrangements: whereas fibrinogen is cleaved by thrombin to form polypeptides A and B, the proteolytic action of other enzymes yields different fibrinogen degradation products. Coagulation Factor I,Factor I,Blood Coagulation Factor I,gamma-Fibrinogen,Factor I, Coagulation,gamma Fibrinogen
D006467 Hemophilia A The classic hemophilia resulting from a deficiency of factor VIII. It is an inherited disorder of blood coagulation characterized by a permanent tendency to hemorrhage. Factor VIII Deficiency,Hemophilia,Autosomal Hemophilia A,Classic Hemophilia,Deficiency, Factor VIII,Factor 8 Deficiency, Congenital,Factor VIII Deficiency, Congenital,Haemophilia,Hemophilia A, Congenital,Hemophilia, Classic,As, Autosomal Hemophilia,Autosomal Hemophilia As,Classic Hemophilias,Congenital Hemophilia A,Congenital Hemophilia As,Hemophilia A, Autosomal,Hemophilia As,Hemophilia As, Autosomal,Hemophilia As, Congenital,Hemophilias, Classic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths

Related Publications

R Scharf, and W Kucharski, and S Lopaciuk, and W Celińska, and A Dmytrow, and K Domański, and S Gonet, and Z Miastkowski, and I Nowakowska, and A Przybylski
January 1995, Seminars in thrombosis and hemostasis,
R Scharf, and W Kucharski, and S Lopaciuk, and W Celińska, and A Dmytrow, and K Domański, and S Gonet, and Z Miastkowski, and I Nowakowska, and A Przybylski
January 1990, Progress in clinical and biological research,
R Scharf, and W Kucharski, and S Lopaciuk, and W Celińska, and A Dmytrow, and K Domański, and S Gonet, and Z Miastkowski, and I Nowakowska, and A Przybylski
February 2003, [Rinsho ketsueki] The Japanese journal of clinical hematology,
R Scharf, and W Kucharski, and S Lopaciuk, and W Celińska, and A Dmytrow, and K Domański, and S Gonet, and Z Miastkowski, and I Nowakowska, and A Przybylski
April 1994, Seminars in hematology,
R Scharf, and W Kucharski, and S Lopaciuk, and W Celińska, and A Dmytrow, and K Domański, and S Gonet, and Z Miastkowski, and I Nowakowska, and A Przybylski
April 2006, Haematologica,
R Scharf, and W Kucharski, and S Lopaciuk, and W Celińska, and A Dmytrow, and K Domański, and S Gonet, and Z Miastkowski, and I Nowakowska, and A Przybylski
November 2001, Haematologica,
R Scharf, and W Kucharski, and S Lopaciuk, and W Celińska, and A Dmytrow, and K Domański, and S Gonet, and Z Miastkowski, and I Nowakowska, and A Przybylski
May 1985, Deutsche medizinische Wochenschrift (1946),
R Scharf, and W Kucharski, and S Lopaciuk, and W Celińska, and A Dmytrow, and K Domański, and S Gonet, and Z Miastkowski, and I Nowakowska, and A Przybylski
October 2000, Haematologica,
R Scharf, and W Kucharski, and S Lopaciuk, and W Celińska, and A Dmytrow, and K Domański, and S Gonet, and Z Miastkowski, and I Nowakowska, and A Przybylski
April 2016, International journal of hematology,
R Scharf, and W Kucharski, and S Lopaciuk, and W Celińska, and A Dmytrow, and K Domański, and S Gonet, and Z Miastkowski, and I Nowakowska, and A Przybylski
June 2002, Seminars in thrombosis and hemostasis,
Copied contents to your clipboard!